Europe Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Biologics and Biosimilar), Source (Microbial and Mammalian), Application (Commercial and Clinical), and Therapeutic Area (Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others)
The Europe Biopharmaceutical Contract Manufacturing Market is projected to grow significantly, reaching an estimated US$ 27,678.2 million by 2031, up from US$ 11,420.5 million in 2024. This growth reflects a robust compound annual growth rate (CAGR) of 13.6% from 2025 to 2031, driven by various factors including increased demand for advanced therapies, a trend towards outsourcing by biopharmaceutical companies, and substantial investments in key markets across the region.
The market is segmented into several key countries: France, Germany, the UK, Italy, Spain, and the Rest of Europe. Notably, Germany, France, and Switzerland are at the forefront, benefiting from established infrastructures and innovation-driven ecosystems. Meanwhile, emerging markets in Central and Eastern Europe, such as Poland and Hungary, are gaining momentum due to their cost advantages and growing technical expertise. The European biopharmaceutical contract manufacturing organizations (CDMOs) are expanding their capabilities in high-growth areas, particularly in biologics, cell and gene therapies, and high-potency active pharmaceutical ingredients (APIs).
Market Segmentation Insights
The Europe Biopharmaceutical Contract Manufacturing Market can be analyzed through various lenses:
The biopharmaceutical industry faces significant financial challenges when it comes to establishing and maintaining in-house manufacturing capabilities for complex biologic products. The high capital and operational expenditures required for setting up and running manufacturing facilities, especially those that necessitate specialized equipment and highly trained personnel, often lead companies to outsource their manufacturing needs to CDMOs. This outsourcing trend allows biopharmaceutical companies to save on costs associated with building and maintaining production plants, making it particularly appealing for smaller firms or startups that may lack the necessary capital.
Outsourcing to CDMOs enables companies to avoid the substantial fixed costs of manufacturing infrastructure, including equipment procurement, facility maintenance, and regulatory compliance. This is especially crucial for the production of specialized products like monoclonal antibodies (mAbs), which are costly and complex to manufacture in-house. The global biopharmaceutical contract manufacturing market is expanding as companies seek cost efficiency and operational flexibility, as highlighted by the U.S. National Academy of Engineering (NAE). The trend towards outsourcing allows biopharma companies to cut capital costs, accelerate production timelines, and adapt to changing market demands.
The dynamic nature of the biopharmaceutical industry, characterized by fluctuating product demand due to market changes, regulatory approvals, and evolving therapeutic needs, further emphasizes the value of CDMOs. These organizations provide flexible scaling options, enabling companies to quickly adjust production volumes without the need for additional investments in facilities or equipment. This flexibility is particularly beneficial during periods of increased demand for biopharmaceutical products. By outsourcing manufacturing, companies can concentrate their resources on core competencies such as drug discovery, while leaving the complexities of production to specialized CDMOs.
Country-Specific Insights
In terms of country-specific performance, Germany is the leading market for biopharmaceutical contract manufacturing in Europe. The country boasts a robust ecosystem of prominent CDMOs, including Richter BioLogics, Boehringer Ingelheim, and Glatt-Integrated Process Solutions, which provide comprehensive services from cell culture to formulation. In 2024, Rentschler Biopharma SE, a notable CDMO, further enhanced its capabilities by constructing a state-of-the-art buffer media station at its headquarters in Laupheim, aimed at improving production efficiency and modernizing its facilities to meet industry demands.
Competitive Landscape
Key players in the Europe Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc., Samsung Biologics Co., Ltd., WuXi Biologics Inc., Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to their clients.
In summary, the Europe Biopharmaceutical Contract Manufacturing Market is poised for significant growth, driven by outsourcing trends, technological advancements, and a focus on cost efficiency and flexibility in manufacturing.
The market is segmented into several key countries: France, Germany, the UK, Italy, Spain, and the Rest of Europe. Notably, Germany, France, and Switzerland are at the forefront, benefiting from established infrastructures and innovation-driven ecosystems. Meanwhile, emerging markets in Central and Eastern Europe, such as Poland and Hungary, are gaining momentum due to their cost advantages and growing technical expertise. The European biopharmaceutical contract manufacturing organizations (CDMOs) are expanding their capabilities in high-growth areas, particularly in biologics, cell and gene therapies, and high-potency active pharmaceutical ingredients (APIs).
Market Segmentation Insights
The Europe Biopharmaceutical Contract Manufacturing Market can be analyzed through various lenses:
- By Product Type: The market is divided into Biologics and Biosimilars, with Biologics holding the largest market share in 2024.
- By Source: The segmentation includes Microbial and Mammalian sources, where Microbial is the leading segment.
- By Application: The market is categorized into Commercial and Clinical applications, with Commercial applications dominating in 2024.
- By Therapeutic Area: This includes Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and others, with Oncology being the largest segment.
The biopharmaceutical industry faces significant financial challenges when it comes to establishing and maintaining in-house manufacturing capabilities for complex biologic products. The high capital and operational expenditures required for setting up and running manufacturing facilities, especially those that necessitate specialized equipment and highly trained personnel, often lead companies to outsource their manufacturing needs to CDMOs. This outsourcing trend allows biopharmaceutical companies to save on costs associated with building and maintaining production plants, making it particularly appealing for smaller firms or startups that may lack the necessary capital.
Outsourcing to CDMOs enables companies to avoid the substantial fixed costs of manufacturing infrastructure, including equipment procurement, facility maintenance, and regulatory compliance. This is especially crucial for the production of specialized products like monoclonal antibodies (mAbs), which are costly and complex to manufacture in-house. The global biopharmaceutical contract manufacturing market is expanding as companies seek cost efficiency and operational flexibility, as highlighted by the U.S. National Academy of Engineering (NAE). The trend towards outsourcing allows biopharma companies to cut capital costs, accelerate production timelines, and adapt to changing market demands.
The dynamic nature of the biopharmaceutical industry, characterized by fluctuating product demand due to market changes, regulatory approvals, and evolving therapeutic needs, further emphasizes the value of CDMOs. These organizations provide flexible scaling options, enabling companies to quickly adjust production volumes without the need for additional investments in facilities or equipment. This flexibility is particularly beneficial during periods of increased demand for biopharmaceutical products. By outsourcing manufacturing, companies can concentrate their resources on core competencies such as drug discovery, while leaving the complexities of production to specialized CDMOs.
Country-Specific Insights
In terms of country-specific performance, Germany is the leading market for biopharmaceutical contract manufacturing in Europe. The country boasts a robust ecosystem of prominent CDMOs, including Richter BioLogics, Boehringer Ingelheim, and Glatt-Integrated Process Solutions, which provide comprehensive services from cell culture to formulation. In 2024, Rentschler Biopharma SE, a notable CDMO, further enhanced its capabilities by constructing a state-of-the-art buffer media station at its headquarters in Laupheim, aimed at improving production efficiency and modernizing its facilities to meet industry demands.
Competitive Landscape
Key players in the Europe Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc., Samsung Biologics Co., Ltd., WuXi Biologics Inc., Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to their clients.
In summary, the Europe Biopharmaceutical Contract Manufacturing Market is poised for significant growth, driven by outsourcing trends, technological advancements, and a focus on cost efficiency and flexibility in manufacturing.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Europe Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Europe
11.1.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.5.6.6 Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.5.6.6.1 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.5.6.6.2 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.5.6.6.3 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.5.6.6.4 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.6.7.7 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.6.7.7.1 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.6.7.7.2 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.6.7.7.3 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.6.7.7.4 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Europe Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Europe
11.1.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Europe Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Germany: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 France: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Italy: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.5.6.6 Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.5.6.6.1 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.5.6.6.2 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.5.6.6.3 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.5.6.6.4 Spain: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.6.7.7 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.6.7.7.1 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.6.7.7.2 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Source
11.6.7.7.3 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Application
11.6.7.7.4 Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. Europe Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 26. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 27. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 28. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 29. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 30. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 31. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 32. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 33. Heat Map Analysis by Key Players
Table 1. Europe Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 26. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 27. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 28. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 29. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 30. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 31. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 32. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 33. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Europe Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Europe Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Europe Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
Figure 1. Europe Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Europe Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Europe Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Europe Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Germany: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. United Kingdom: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. France: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Italy: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Spain: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of Europe: Europe Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
